Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
Heterocyclic compounds are developed to activate TREM2, addressing the neuroimmune aspects of neurodegenerative diseases by enhancing microglial responses and reducing disease pathology.
AU2024399431A1Pending Publication Date: 2026-07-23VIGIL NEUROSCIENCE INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- VIGIL NEUROSCIENCE INC
- Filing Date
- 2024-12-12
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Current therapies fail to effectively target the neuroimmune aspects of neurodegenerative diseases by activating the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), which are implicated in conditions like Alzheimer's disease and other neurological disorders.
Method used
Development of heterocyclic compounds that act as TREM2 agonists, capable of activating the receptor to modulate microglial responses and improve neuroimmune function.
Benefits of technology
The compounds enhance microglial activation, potentially reducing plaque burden and altering pathological hallmarks of neurodegenerative diseases, providing a therapeutic approach to treat or prevent conditions associated with TREM2 loss-of-function.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Need to check novelty before this filing date? Find Prior Art